Company intelligence / Profile preview
Akagera Medicines
Waltham/Boston, Massachusetts, USAakageramedicines.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Akagera Medicines has completed the first cohort in a Phase 1 SAD/MAD study of AKG-100—a long acting injectable oxazolidinone antibiotic—for pulmonary tuberculosis. Preclinical proof-of-concept has been achieved in MDR-TB and MRSA with strong efficacy and low toxicity. Multiple vaccine candidates are advancing toward human safety trials by 2026
- Therapeutic areas
- Infectious Diseases
- Modalities
- Liposomal formulationLipid nanoparticlemRNA-based drugsSmall molecule
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Coalition for Epidemic Preparedness Innovations (CEPI)Bill & Melinda Gates FoundationNational Institutes of Health – Vaccine Research Center (NIH VRC)European Investment Bank/EU CommissionPublic pharmaceutical company partner not named explicitly
Beyond the preview
Go deeper on Akagera Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akagera Medicines.